PURE (PURE Bioscience) Beginning Cash Position: $0.27 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PURE Bioscience Beginning Cash Position?

PURE Bioscience PURE +13.17% Beginning Cash Position is $0.27 Mil as of Apr. 2026. The stock has 5 warning signs investors should review.

PURE Bioscience's Beginning Cash Position for the quarter that ended in Apr. 2026 was $0.27 Mil.

PURE Bioscience's quarterly Beginning Cash Position increased from Oct. 2025 ($0.41 Mil) to Jan. 2026 ($0.51 Mil) but then declined from Jan. 2026 ($0.51 Mil) to Apr. 2026 ($0.27 Mil).

PURE Bioscience's annual Beginning Cash Position declined from Jul. 2023 ($3.47 Mil) to Jul. 2024 ($1.17 Mil) and declined from Jul. 2024 ($1.17 Mil) to Jul. 2025 ($0.42 Mil).

PURE Bioscience Beginning Cash Position Related Terms

PURE Bioscience Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for PURE Bioscience's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PURE Bioscience Beginning Cash Position Chart

PURE Bioscience Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.91 2.47 3.47 1.17 0.42

PURE Bioscience Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.62 0.41 0.51 0.27

PURE Bioscience Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.27 Mil mean?
PURE Bioscience (PURE) has a Beginning Cash Position of $0.27 Mil as of Apr. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PURE Bioscience and its competitors.
Is PURE Bioscience's Beginning Cash Position too high?
PURE Bioscience's current Beginning Cash Position is $0.27 Mil.
How does PURE Bioscience's Beginning Cash Position compare to DQWS and RAY?
PURE Bioscience's Beginning Cash Position of $0.27 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Consumer Packaged Goods company?
A good Beginning Cash Position depends on the Consumer Packaged Goods industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PURE Bioscience and its competitors. PURE Bioscience's current Beginning Cash Position is $0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PURE Bioscience stock overvalued right now?
Based on GuruFocus' analysis, PURE Bioscience (PURE) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.10, compared to a current price of $0.08 — trading 23.3% below its estimated fair value. The current Beginning Cash Position is $0.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For PURE Bioscience (PURE), the current Beginning Cash Position is $0.27 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PURE Bioscience Business Description

Address 771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, and products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The company generates revenue from the sale of its antimicrobial products.